CURRICULUM VITAE

**DAVID F. MOBLEY, M.D., FACS**

Date of preparation: Jan 10, 2018

**A. GENERAL INFORMATION**

Office Address: Methodist Urology Associates

 Houston Methodist West Hospital

 Professional Building No. 1

 18300 Katy Freeway, Suite 325

 Houston, Texas, 77094

Office Telephone: 832-522-8300

Office Fax: 832-522-8301

Home Address: 11327 Noblewood Bend, Houston, Texas 77082

Home Telephone: 281-493-5555

Cell Phone: 281-235-5158

E-mail: DFMobley@houstonmethodist.org

mobleyresearch@gmail.com

Citizenship: USA

**Optional Information:**

Birth Date: November 20, 1942

Birth Place: San Francisco, CA.

Marital Status: Married

Spouse’s Name: Pat Mobley

Children’s Names/Ages: four children

Race/Ethnicity: Caucasian

**B. EDUCATIONAL BACKGROUND**

# Degree Institution Name, City, State Dates Attended Year Awarded

B.A. Chemistry

University of Arizona 9/1960-1965 5/1965

 Tucson, Arizona

 Arizona State University 7/1963-8/1963

M.D. University of Tennessee 9/1965-12/1968 12/1968

 Memphis, Tennessee

Graduate Certificate in Healthcare Management 1/2006-12/2006 12/2006

Executive Education-Healthcare

 Rice University, Houston, TX

**C. PROFESSIONAL POSITIONS AND EMPLOYMENT**

 **Post-doctoral training including residency/fellowship**

# Title Institution Name, City, State Dates

Internship University of Tennessee College of Medicine 7/1969-6/1970

 Memphis, Tennessee

Surgery Residency Baylor College of Medicine 7/1970-6/1971

 Houston, Texas

Urology Residency Baylor College of Medicine 8/1973-6/1977

 Houston, Texas

 **Academic positions (teaching and research)**

#  Institution Name, City, State Dates

Clinical Instructor Department of Pathology 7/1967-12/1968

 University of Tennessee Medical School

 Memphis, Tennessee

Associate Professor Institute for Academic Medicine 7/2014-present

 Houston Methodist Hospital

 Houston, TX

Associate Clinical Professor Weill-Cornell Medical College 10/2015-

 **Hospital positions (attending physician, if applicable)**

# Title Institution Name, City, State Dates

Active Staff Memorial HermaHermann Memorial City Hospital 8/1977-present

 Houston, TX

Courtesy Staff Memorial Hermann Katy Hospital 1/1995-2/2012

 Houston, TX

Courtesy Staff Spring Branch Memorial Hospital 2/1997-6/2000

 Houston, TX

Active Staff Memorial Village Surgical Center 1/2010-present

 Houston, TX

Active Staff Houston Methodist Hospital West Houston 5/2011-present

 Houston, TX

Active Staff Houston Methodist Hospital 5/2012-present

 Houston, TX

 **Employment (other than positions listed above)**

# Title Institution Name, City, State Dates

Teaching Assistant Department of Pathology 7/1967-12/1968

 University of Tennessee, Memphis, TN

Physician Assistant/ Medical Clinic of West Memphis 1/1969-6/1969

Physician West Memphis, AR

Major, MC United States Air force 8/1971-8/1973

Urologist Private Practice 8/1977-7/2010

 Houston, TX

Urologist Texas Oncology 8/2012-12/2011

 Houston, TX

**D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE (if applicable)**

**Licensure**

# State Number Date of Issue Date of Expiration

Texas D6666 1971 June 30, 2015

**DEA Number:** AM4822210

## Board Certification

### Name of Specialty Board Certificate Number Date of Certificate

American Board of Urology 7256 Feb 5, 1980

## Malpractice Insurance

Do you have Malpractice Insurance? Yes

Name of Provider: The Methodist Hospital Trust

Premiums Paid By: Houston Methodist Specialty Physician Group

**E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies)**

# Member/Officer Name of Organization Dates Held

Fellow American College of Emergency Physicians 1974-1978

Member Harris County Medical Society 1977-present

Member Texas Medical Association 1977-present

Member American Fertility Society 1978-1990

Member American Society of Andrology 1978-1990

Fellow American College of Surgeons 1981-present

Member American Urological Association 1982-present

South Central Section

Member American Society of Undersea Medicine 1990-1995

Member American Society for Lasers in Medicine and Surgery 1990-2000

Fellow Interamerican College of Physicians and Surgeons 1995-1998

Member Endourological Society 1995-2000

Member Texas Medical Foundation-Peer Review Organization 2000-2001

Corresponding Member Academia Peruana Cirugia 2000-2002

(\*some dates are estimated)

Member Society for Urodynamics and 2014-present

Female Pelvic Medicine (SUFU)

**F. HONORS AND AWARDS**

# Name of Award Year Awarded

Outstanding Urologic Research Award 1974, 19775

Baylor College of Medicine

First Place Award: Resident Essay Competition 1976

South Central Section

American Urological Association

First Place Award 1977

Texas Chapter American

College of Surgeons (surgical research study)

Cullen Award for Urologic Research 1977

Baylor College of Medicine

Second Place Award 1979

Western Section

American Urological Association (Resident Essay Contest)

Physicians Recognition Award 1977, 1978, 1980, 1981, American Medical Association 1982, 1984, 1987, 1990,

 1993, 1998, 2000

Physician of the Year 1992

Memorial City Medical Center

**G. INSTITUTIONAL/HOSPITAL AFFILIATION**

Primary Hospital Affiliation: Houston Methodist West Hospital

Other Hospital Affiliations: Memorial Hermann Memorial City Hospital

 Houston Methodist Hospital

Other Institutional Affiliations: Memorial Hermann Surgery Center Memorial Village

**H. EMPLOYMENT STATUS**

Name of Employer: Houston Methodist Specialty Physician Group

Employment Status:

* Full-time salaried at Cornell-affiliated hospital

**I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT**

#### Teaching (list courses and your role) Dates

Private Practice until 2012

**Coloplast and American Medical Systems** (vendors) 1980-2005

Proctored penile implant surgeries with physicians in residency (about 25 residents)

**Academia Peruana de Cirugia**  3/2000

**Hospital Nacional Edgardo Rebagliati Martins**

Lima, Peru

Proctored penile implant surgeries with 70 doctors

**Memorial City Medical Center** 2002-2004

Proctored penile implant surgeries with Junior and Senior medical students from UTMB- Galveston

**Houston Methodist Hospital**

I will be involved with training residents and fellows through 2012-Present

Weill Cornell, under the auspices of department chair,

Dr. Timothy Boone.

#### Clinical Care Dates

Full time urologist 8/1977-Present

I have areas of special experience in the management of males and females with urinary incontinence and in males with erectile dysfunction. This entails medical and surgical care of urology patients and active clinic trial experience.

#### Administrative Duties (including committees) Dates

Population Program Action Committee 1/1975-12/77

Baylor College of Medicine

Credentials Committee, Memorial City Medical Center 1/1978-12/1979,

1/1981-12/1982

1/1989-12/1990

Emergency Committee, Memorial City Medical Center 1/1980-12/1981,

1/1988-12/1991

Board of Directors, Bayou City IRB 1/1980-12/1988

Chief, Urology Section, Department of Surgery 1/1981-12/1981,

Memorial City Medical Center 1/1983-12/1983,

1/1985-12/1985,

1/1990-12/1990,

 1/1993-12/1993

 (each term one calendar yr)

Chairman, Emergency Committee, Memorial City Medical Center 1/1983-12/1983,

1/1985-12/1985

 (each term one calendar yr)

Director: Center for Overcoming Impotence 1/1985-12/1990

Memorial City Medical Center, Houston

Vice-President Medical Staff, Memorial City Medical Center 1/1988-12/1988

(one calendar year)

President-Elect, Medical Staff, Memorial Medical Center 1991 (Jan-Dec)

President, Medical Staff, Memorial City Medical Center 1992 (Jan-Dec)

Memorial City Medical Center, Disaster Team 1990, 1991, 1992

 (each Jan-Dec)

Medical Records Committee, Memorial City Medical Center 1991(Jan-Dec)

Chairman, Bylaws Committee, Memorial Hospital Memorial City 1994 (Jan-Dec)

Board of Directors, Memorial Hermann Foundation 1/1995-12/2003

Investigational Research Review Board,

Memorial Hermann Healthcare Hospital System 1/1995-12/2000

Chairman, Department of Surgery, Memorial Hospital, Memorial City 1998 (Jan-Dec)

Cancer Committee- Methodist West Houston 1/2012-present

Ethics Committee- Methodist West Houston 1/2012-present

Enhanced Recovery After Surgery (ERAS) Steering Committee 3/2015-present

Methodist West Houston

Grant Review Committee- Houston Methodist Hospital 5/2015

***Research***

Clinical Research 8/1977-present

 Principal Investigator in approximately 100 clinical trials

20% of my professional time has been/is involved in clinical trial work. Research interests include any urological condition; medical, surgical or device-related; both benign and malignant conditions.

In addition I am fairly experienced in type II diabetes mellitus research and I am interested in phase II, III and IV studies (reference industry funded studies: #39, 51, 53, 63, 69, 83, 91, 92).

I have also been involved in research studies for patients with Postherpetic Neuralgia (reference industry funded studies: 71, 72, 84)

# **Current Percent Effort (%)** Does the activity involve WCMC

# students/researchers? **No**

      Teaching 5

      Clinical Care 75

      Administration 5

      Research 15

      Total: 100

**Section J. RESEARCH SUPPORT (past and present)**

**Completed Industry Funded Studies**

1. Principal Investigator; "A Multicenter Comparison of the Safety and Efficacy of Lomefloxacin vs. Ofloxacin in the treatment of Bacterial Prostatitis Protocol #S69-91-02-196 G.D. Searle & Co. 1974-1977
2. Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Investigate the Long-Term Effects of Finasterde (MK-906) in Patients with Benign Prostatic Hyperplasia." Protocol 048-04/GHBA-909. Merck Research Laboratories/G.H. Besselaar Associates. 1977-1979.
3. Principal Investigator; "A Phase II Dose Ranging Efficacy Study of Oral Zanoterone, A New Steroidal Androgen Receptor Antagonist, In Men with Symptomatic Benign Prostatic Hyperplasia" Protocol #49596-005. Sterling Drug Co. 1980-1982.
4. Principal Investigator; "A Phase II dose Ranging Safety and Efficacy Study of Oral Zanoterone in Subjects with Stage D2 Carcinoma of the Prostate," Protocol #49596-204. Theradex/Sterling Winthrop Pharmaceuticals. 1980-1982
5. Principal Investigator; "Doxazosin vs. Placebo in the management of symptomatic B.P.H." A double-blind placebo-controlled long term study with a long-term open label branch. Pfizer Inc. 1980-1982
6. Principal Investigator; "A One-Year, Multicenter, double-Blind Comparison of the effects of SKF 105657 vs. Placebo in the treatment of symptomatic B.P.H. With Six Month Untreated Follow-Up," Protocol 105657/018. Smith Kline Beecham Pharmaceuticals. 1980-1982.
7. Principal Investigator; "A Randomized Double-Blind Placebo-Controlled Parallel Study to Assess the Efficacy and Safety of Four Dose Levels of RS-15385 in Men with Erectile Disorder." Protocol #92CE28-0606. Syntex Development Corp. 1982-1984
8. Principal Investigator; "A Twenty-Six Week, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension Using Doxazosin Tablets for the Treatment of Benign Prostatic Hyperplasia," Protocol #92CE28-0606 Pfizer Central Research, Inc. 1982-1984.
9. Principal Investigator; "A Randomized Pilot Study to Assess the Efficacy and Safety of Two Oral Dose Levels of Delaquamine HCl in Men With Erectile Disorder." Protocol #DELS2282-Syntex Development Research. 1982-1984.
10. Principal Investigator; "A Phase II Dose Finding Placebo Controlled Study of Four Dose Levels of YM617 in Patients with Signs and Symptoms of Benign Prostatic Hyperplasia." Protocol #YM617US90-01. Yamanouchi Pharmaceutical Company L\, Ltd./Oxford Research International Corporation. 1983-1985.
11. Principal Investigator; "Ro 23-6240 (Fleroxacin) in Uncomplicated Urinary Infections in Women. A Randomized, double Blind, Prospective Study Versus Ciprofloxacin" Protocol #N3606B. Hoffman-La Roche. 1983-1985.
12. Principal Investigator; "A Sixteen-Week, Double-Blind, Placebo-Controlled Dose Response Study Using Doxazosin Tablets For the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients," Protocol #90CE28-0488. Pfizer, Inc. New York. 1983-1985.
13. Principal Investigator; "A Phase II/III Open-Label, Long-Term, Follow-up Safety Study of Oral Zanoterone in Men with Symptomatic Benign Prostatic Hyperplasia." Protocol #49496-006. Sterling Winthrop Pharmaceuticals Research Division. 1983-1985.
14. Principal Investigator; "A One-Year Multicenter, Double-Blind Comparison of the Effects of Once-Daily Dosing with Three Dose Levels of SK&F 105657 or Placebo in the Treatment of Symptomatic Benign Prostatic Hyperplasia with Six-Month Untreated Follow-up," Protocol # 15385S2280. Syntex Development Research. 1984-1986.
15. Principal Investigator; "A Two-Year, Open-Label, Multicenter Study of Oral Epristeride 80mg.Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #10560/051. SmithKline Beecham Pharmaceuticals. 1984-1986.
16. Principal Investigator; "A One-Year, Open Label, Multicenter Study of Oral Epristeride 80mg. Once Daily in the Treatment of Benign Prostatic Hyperplasia," Protocol #105657/051. SmithKline Beecham Pharmaceuticals. 1984-1986.
17. Principal Investigator; Part A *-* "Clinical Efficacy and Safety of Two Doses of Tolterodine Compared to Placebo, A Phase III Randomized, Double Blind, Multinational Study in Patients With Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence and Urgency." *Part B -* Long-Term Safety, Tolerability and Clinical Efficacy of Tolterodine-A phase III, Open, Multinational Study in Patients with Detrusor Over-Activity and Symptoms of Frequency, Urge Incontinence, and Urgency." Protocol 940ATA009-923. Pharmacia, Inc. 1985-1987.
18. Principal Investigator; A Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Evaluation of GII98745 and Finasteride in Subjects with Benign Prostatic Hyperplasia" Protocol #ARIA2001. Glaxo Wellcome, Inc. 1985-1987.
19. Principal Investigator; "A Five-Month, double Blind, Placebo-Controlled, Randomized Multicenter Cross-Over Study of the Effects and Safety of Testosterone Transdermal System (TTD System) in Men Presenting with Sexual Dysfunction and Serum Testosterone Levels <350ng./dl/" Protocol #TT1000/002. SmithKline Beecham Pharmaceuticals/Clinical Trials, Inc. 1985-1987.
20. Principal Investigator; "A Double-Blind, Randomized, Placebo-Controlled Parallel Group, Multicenter, Flexible Dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with Erectile Dysfunction" Protocol #148-103 (CBI-1171). Pfizer/Corning Besselaar. 1985-1987.
21. Principal Investigator; "A Double-Blind, Placebo-Controlled, dose-Ranging Clinical Evaluation of G1231818 In Subjects with Benign Prostatic Hyperplasia" Protocol #A1A2001,, Glaxo Wellcome Inc/Clinical Trials Research, Inc. 1985-1987.
22. Principal Investigator; "A Phase III Efficacy and safety Study of Three Fixed doses of Apomorphine SL Tablets Versus Placebo in the treatment of Male Erectile Dysfunction" M96-470, Tap Holdings./IBRD. Rostrum Global. 1986-1988.
23. Principal Investigator; "The Maximum Tolerated and Minimum Effective Dose of OROS in the Treatment of Patients with Urge or Mixed Urinary Incontinence." C95-049-02. ALZA Corporation. 1986-1988.
24. Principal Investigator; "A Double-Blind, Placebo-Controlled Crossover Design Study to Evaluate the Effects of Three Single Doses of a Selective Alpha-1 Adrenoreceptor Antagonis RS-100975-190 on Peak Urinary Flow Rate in Men with Benign Prostatic Hyperplasia (BPH)" S2679. Roche Bioscience. 1986-1988.
25. Principal Investigator; "A Double-Blind, Placebo Controlled, Parallel, Fixed Dose Study of Sertraline In The Management of Premature Ejaculation. Protocol 96CE21-0702. Pfizer Pharmaceuticals. 1987-1989.
26. Principal Investigator; Prospective Study for Urethrin Implant used in the Treatment of Urinary Incontinence. Protocol G930198. Mentor Urology. 1987-1989.
27. Principal Investigator; Evaluation of the Safety and Efficacy of MUSE plus the ACTIS Venous Flow Controller in Men with Erectile Dysfunction. Protocol AV-01. Vivus, Inc. Menlo Park, CA. 1987-1989.
28. Principal Investigator; An Open-Label trial of Oral Phentolamine in Patients with Mild to Moderate Erectile Dysfunction. Protocol ZON 303. Zonagen, Inc. The Woodlands, Texas. 1987-1989.
29. Principal Investigator: A prospective Study of Mentor Alpha-1 Penile Implant in Men with Organic Impotence. Mentor Urology. Santa Barbara CA. 1988-1990.
30. Principal Investigator; A Prospective Study of the Efficacy and Reliability of the DP9010 Inflatable Penile Prosthesis. A Phase III Study. American Medical Systems. Minnetonka, MN. 1989-1991.
31. Principal Investigator; A Phase III Efficacy and Safety Study Comparing Escalating Doses of Apomorphine SL to 5 or 6 mg. Doses of Apomorphine SL or Placebo in the Treatment of Male Erectile Dysfunction. Protocol Number M97-763. Tap Holdings, Inc. 1989-1991.
32. Principal Investigator; Benign Prostatic Hyperplasia (BPH): Effectiveness of Terazosin Therapy in Patients Treated With Finasteride. Abbott/SCP Principal Investigator: Duloxetine versus placebo in the relief of stress incontinence. Protocol FIJ-MC-SAAW(a). Eli Lilly Inc. 1989-1991.
33. Principal Investigator; Efficacy and Safety of Alfuzosin Once Daily Tablets at Two dosage Levels Versus Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia. Protocol 2650. Synthelabo. 1989-1991.
34. Principal Investigator; A Randomized, Double-blind Comparative trial Of Biclutamide 150mg. Versus Placebo Each in Combination with Castration as Second-line Therapy in Patients with Asymptomatic Metastatic Prostate Cancer. Protocol 7054US/0007. Zeneca Pharmaceuticals. 1990-1992.
35. Prinicpal Investigator; A Dose-Range Finding Double-Blind, Randomized, Placebo-controlled, Multicenter, Active Comparator Study to Determining the Effect of L-753099 in Postmenopausal Women with Predominately Urge Urinary Incontinence. Protocol 011-00Draft. Merck Research Laboratories. 1990-1992.
36. Principal Investigator; A Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Fixed-dose, Dose-Ranging Study to Assess the Safety and Efficacy of Daily Administration of a Single Oral Dose of YM905 in male and Female Patients with Urge Urinary Incontinence. Protocol 905-CL-006. Yamanouchi USA, Inc. 1990-1992.
37. Principal Investigator; Long term Compliance of Oral Supplements by Oncology Outpatients in Need of Nutritional Support. Project 7081 Protocol 9912. Mead Johnson Nutritionals. 1990-1992.
38. Prinicipal Investigator; A Study on Incidence of Autoinflation with the American Medical Systems 700 Series Inflatable Penile Prosthesis. Protocol AMS99-003. American Medical Systems. 1990-92.
39. Principal Investigator; A randomized, double-blind, placebo-controlled, multi-center, fixed dose, parallel group, 3-month comparison study to investigate the efficacy and safety of the phosphodiesterase Type V inhibitor BAY 38-9456 in males with erectile dysfunction and diabetes mellitus. Bayer Pharmaceutical Divison. West Haven CT. 1991-92.
40. Principal Investigator; Double-blind, randomized, placebo-controlled, parallel group study of the efficacy and safety of darifenacin versus tolterodine in the treatment of subjects with overactive bladder. Protocol A1371001 Pfizer Pharmaceuticals, NY. 1991-93.
41. Sub-Investigator; A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Comparing Oxybutinin Transdermal Systems versus Tolterodine Long-Acting Capsules in Patients with Overactive Bladder. Protocol O00011. Watson Pharmaceuticals. Salt Lake City UT. 1991-93.
42. Principal Investigator; A Randomized, Placebo-Controlled, Double-Blind, Parallel Design, Phase 3 Trial of the Efficacy and safety of Alprox-TD in Male Patients with Erectile Dysfunction. Protocol No MED 2000-DDS NexMed, Inc. 1991-93.
43. Principal Investigator; Protocol FIJ-MC-SBAY Long Term Monitoring of Safety in Subjects Treated with Duloxetene for Stress Urinary Incontinence. Lilly Pharmaceuticals. Indianapolis, IN. 1992-94.
44. Principal Investigator; Trial 526.26, A two phase, double blinded, randomized, parallel group design, multicenter study of Flomax capsules, 0.4 mg. Versus placebo in male patients with acute urinary retention related to benign prostatic hyperplasia. Boehringer Ingelhem, Inc. 1993-95.
45. Principal Investigator, A 6-Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group, Multicenter, Multidose Study of the Efficacy and safety of KW-7158 in Patients with Overactive Bladder Symptoms of Increased Urinary Frequency, Urgency and Urge Incontinence. Study 71580INT-001. Kyowa Pharmaceutical, Inc. 1994-96.
46. Principal Investigator; A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Rofecoxib in Decreasing the Risk of Prostate Cancer. Protocol MK-0966-201. Merck, Inc. 1994-96.
47. Principal Investigator; A Randomized, Placebo-Controlled, Parallel Group Study of the efficacy and safety of Dutasteride 0.5 mg. Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer. The REDUCE Trial. Protocol ARI4006. 1997-99.
48. Principal Investigator; A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and reliability of 20mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 20mg vardenafil. Study #BAY38-9456/100497. Bayer. 1997-99.
49. Principal Investigator; A double blind, placebo controlled, randomized US/Latin America study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder. Protocol 583E-URO-0084-037, IND#56,406. Pfizer/Pharmacia. 1997-99.
50. Principal Investigator; A six month open label, randomized multi-center study to evaluate the comparative efficacy and safety of oral Famvir in the episodic and suppressive treatment of recurrent genital herpes. Protocol CFAM810A US07, Novartis Pharmaceuticals. 1997-99.
51. Principal Investigator; A Multi-center, double-blind, Randomized, Active-Controlled Parallel Group Study to Evaluate the Lipid-altering Efficacy of MK-0767 in Patients with Type 2 Diabetes and Dyslipidemia. Protocol 034. Merck Inc. 1997-99.
52. Principal Investigator; A Multicenter, Open Label, Flexible Dose Study To Investigate the Use of Patterns of Viagra (sildenafil citrate) and the Ability of Investigators to Further Optimize Subject Satisfaction with Viagra Through Customized Instruction. Protocol A1481179. Pfizer, Inc. 1997-99.
53. Principal Investigator; A Multi-center, Double-blind, Randomized, Active Controlled Parallel Study in Patients with Type 2 Diabetes to Evaluate the Cardiac and Metabolic Effects of MK-0767. Protocol #018 Merck Pharmaceuticals Inc. 1997-99.
54. Principal Investigator; A Randomized, double-blind, Multicenter, Placebo-controlled, Parallel group study to Evaluate the Efficacy and Safety of Valsartan (320mg.) and Hydrochlorthiazide (12.5 and 25mg) combined and alone, Valsartan 160 mg. and Valsartan 160 mg/Hydrochorthiazed 12.5 mg in Hypertensive Patients. Study No CVAH631C2301. Novartis Pharmaceuticals Corporation. 1997-99.
55. Principal Investigator; Study of Duloxetine DCl in women of Different Demographic characteristics and Co-morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety. Protocol F1J-US-SBCD. Eli Lilly & Co. 1997-99.
56. Principal Investigator; An Open-Label stuidy to Evaluate the Efficacy and Safety of Tadalafil Aministered “On Demand” to Men of Various Populations with Erectile Dysfunction. Protocol No.: H6D-MC-LVFN(b) Lilly Icos. 1997-99.
57. Principal Investigator; An Open-Label Study of the efficacy and safety of 5 and 10 mg Vesicare (Solifenacin Succinate) in Patients with Overactive Bladder Symptoms. Protocol 905-UC-007. Yamanouchi Pharma America, Inc. 1997-99.
58. Principal Investigator; a Phase 2b, Multi-center, double-blind, Placebo-controlled, Parallel group Dose Response Study to Assess the Efficacy and safety of Oral UK-390,957 in Men With Premature Ejaculation. Pfizer Inc. Protocol #A3871022. 1998-2000.
59. Principal Investigator; A Randomized, double-blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin 20 gm in the Primary Prevention of Cardiovascular events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels C-Reactive Protein. Protocol No 4522US/0011. AstraZeneca. 1998-2000.
60. Principal Investigator; A Randomized, Double-Blind, Placebo controlled, Four Arm Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4mg in Men Who Have Frequency and Urgency, With or Without Urinary Urge Incontinence, With or Without Bladder Outlet Obstruction. Protocol #A621120. Pfizer Inc. 1998-2000.
61. Principal Investigator; A Phase 2, 8 week, Multi-center, Randomized Double-blind, Placebo controlled, Parallel; Group Study evaluating the Efficacy, Tolerability and Safety of (S,S)-REBOXETINE (PNU-165442G) for Stress Urinary Incontinence in Women. Protocol A6061023. Pfizer Pharmaceuticals, Inc. 1999-2001.
62. Principal Investigator; A 12 week, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy of Enablex® (darifenacin) 15 mg OD on increase in warning time, the time from first sensation of urgency to voiding, in patients with Overactive Bladder (OAB). Protocol DAR328A2401. Novartis Pharmaceuticals Corp. 1999-2001.
63. Principal Investigator; A multicenter, randomized, double blind study of MK-0431 in patients with Type 2 Diabetes Mellitus who have inadequate Glycemic Control. Protocol 023. Merck & Co., Inc. 1999-2001.
64. Principal Investigator; A Phase 2 multicenter, open label, long term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. Protocol A3871028. Pfizer. 2000-2002.
65. Principal Investigator; A Phase 2B, multicenter, double blind, placebo controlled, flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. Protocol A3071029. Pfizer. 2000-2002.
66. Principal Investigator; A multicenter, double blind, randomized, placebo controlled, parallel group, dose ranging of L-000796568 in postmenopausal women with overactive bladder. Protocol 024. Merck & Co., Inc. 2001-2003.
67. Principal Investigator; A double blind, multicenter, randomized, placebo controlled study of safety and efficacy of trospium chloride 60 mg modified release capsules versus placebo, once daily, for 12 weeks followed by a 9 month, open label treatment phase in patients with overactive bladder. Protocol IP631-022. Indevus Pharmaceuticals, Inc. 2001-2003.
68. Principal Investigator; A multicenter, double blind, placebo controlled, flexible dose study with an open label phase to assess the efficacy of sildenafil citrate on erectile function and intercourse satisfaction and validate the sexual experience questionnaire and investigate treatment responsiveness to sex-q in men with erectile dysfunction. Protocol 1481236. Pfizer. 2001-2003.
69. Principal Investigator; A multicenter, randomized, double-blind, placebo controlled, Phase 3 trial to evaluate the efficacy and safety of saxagliptin (BMS-477118) in combination with thiazolidinedione therapy in subjects with Type 2 Diabetes who have inadequate glycemic control on thiazolinedione therapy alone. Bristol-Myers Squibb. 2002-2004.
70. Principal Investigator; A two-arm, open label, randomized, multi-center pharmacokinetic and long term safety study of intramuscular injections of 750 mg and 1000 mg testosterone undecanoate in hypogonadal men. Indevus Pharmaceuticals, Inc. 2003-2005.
71. Principal Investigator; [S,S]-Reboxetine dose-range finding trial: A 16-week, randomized, double blind, placebo and pregabalin controlled, multi-center trial of [S,S]-reboxetine in patients with Postherpetic Neuralgia (PHN). Pfizer, Inc. 2004-06.
72. Principal Investigator; An open label extension trial assessing the safety and tolerability of [S,S]-Reboxetine in patients with Postherpetic Neuralgia (PHN). Pfizer, Inc. 2004-2006.
73. Principal Investigator; A randomized, double blind, placebo controlled, parallel group, multicenter safety and efficacy, Phase 4 study of Vesicare® (Solifenacin Succinate) or placebo in combination with tamsulosin hcl for the treatment of residual OAB symptoms of urgency and frequency in men. Astellas Pharma US, Inc. 2005-2007.
74. Principal Investigator; A four-arm, randomized, double blind, parallel, placebo controlled, exploratory study of pagoclone 0.15 mg, 0.30 mg, and 0.60 mg in men with primary premature ejaculation. Indevus Pharmaceuticals, Inc. 2005-2007.
75. Principal Investigator; A multicenter, double blind, placebo controlled study of the efficacy and safety of daily dosing with oxybutinin topical gel to treat the symptoms of overactive bladder. Watson Laboratories, Inc. 2006-2008.
76. Principal Investigator; A randomized, double blind, placebo controlled Detrol LA “Add-On” to alpha blocker study in men with persistent overactive bladder symptoms of urinary frequency and urgency with/without urgency incontinence after previous monotherapy with alpha blocker. Pfizer, Inc. 2006-2008.
77. Principal Investigator; A multicenter, placebo controlled, randomized, double blind, dose ranging study of SVT-40776 in patients suffering from overactive bladder syndrome (OAB). Salvat Laboratorios. 2006-2008.
78. Principal Investigator; A randomized, double blind, placebo controlled, multi center, Phse 3 study of denosumab on prolonging bone metastasis free survival in men with prostate cancer. Amgen, Inc. 2007-2009.
79. Principal Investigator; Lipid Treatment Assessment Project 2 (L-TAP2). Pfizer, Inc. 2008-2010.
80. Principal Investigator; A 12-week, multicenter, open label, single arm study to evaluate the effects of fesoterodine on treatment satisfaction and symptom relief in overactive bladder patients. Pfizer, Inc. 2009-2011.
81. Principal Investigator; 12-week, randomized, double blind, double dummy, placebo controlled, parallel group, multicenter trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine ER in patients with overactive bladder. Pfizer, Inc. 2009-2011.
82. Principal Investigator; A Phase 3 randomized, open label study of CG1940 CG8711 versus docetaxel and prednisone in patients with metastatic hormone refractory prostate cancer who are chemotherapy naïve. Cell Genesys, Inc. 2009-2011.
83. Principal Investigator; A multicenter, randomized, open label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with vildagliptin 100 mg qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community based practice setting. Novartis Pharmaceuticals Corp. 2010-12.
84. Principal Investigator; [S,S]-Rebozetine add-on trial: A randomized, double blind, placebo controlled, multicenter trial of [S,S]-Reboxetine in patients with postherpetic neuralgia (PHN) concomitantly treated with pregabalin. Pfizer, Inc. 2010-12.
85. Principal Investigator; A randomized, double blind, parallel group study of cardiovascular safety in osteoarthritis or rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celocoxib with naproxen and ibuprofen. Pfizer, Inc. 2010-12.
86. Principal Investigator; A Phase 3 randomized, open label study of docetaxel in combination with CG1940 and CG8711 versus docetaxel and prednisone in taxane-naïve patients with metastatic hormone refractory prostate cancer with pain. Cell Genesys, Inc. 2010-12.
87. Principal Investigator; A Phase 2, randomized, double blind, parallel group, placebo controlled, multicenter, study to evaluate the safety of the co-administration of solifenacin succinate with 0.4 mg tamsulosin hydrochloride OCAS (TOCAS) using urodynamics in male subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO). Astellas Pharma US, Inc. 2010-12.
88. Sub-Investigator; A randomized Phase 2 study of the anti-angionesis agent AG-013736 in combination chemotherapy and bevacizumab in patients with metastatic colorectal cancer preceded by a Phase 1 portion. Pfizer, Inc. 2010-12.
89. Sub-Investigator; A randomized, double blind Phase 3 study of gemcitabine plus AG-013736 versus gemcitabine plus placebo for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. Pfizer, Inc. 2010-12.
90. Principal Investigator; PROLIEVE;Post-Marketing Study Using Prolieve for the treatment of BPH. Boston Scientific Corp. 2009-2012.
91. Principal Investigator; HARMONY 4 GLP112754; A Randomized, Open-Label Parallel Group Multicenter Study to Determine the Efficacy and Long Term Safety of Abiglutide Compared with Insulin in Subjects ith Type 2 Diabetes Mellitus. GSK. 2011-2012.
92. Principal Investigator; LX4211.1-202DM; A Phase II, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination with Metformin in Subjects with Type II Diabetes Mellitus. Lexicon Pharmaceuticals. 2011-2012.

**Current Protocols (Industry Funded):**

1. Principal Investigator; NX02-0018;Phase III Multicenter Prospective Randomized Parallel Group Placebo Controlled Double-Blind Clinical Evaluation of NX-1207 for the Treatment of BPH. Nymox Pharm. 2011-ongoing (1% effort). $27,076.
2. Principal Investigator; NX02-0020;Phase III Multicenter Open Label Safety Evaluation of Re-injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 years apart. Nymox Pharm, 2011-ongoing. (2% effort) $25,763.55
3. Principal Investigator; 905-UC-050; A randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to assess Efficacy and Safety of VESIcare (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy. 2011-ongoing. (2% effort) $7,750.00
4. Principal Investigator; SPC-120-DB-201101; A Randomized, Double-Blind, Placebo-Controlled Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients with Nocturia. Serenity Pharmaceuticals; 2010-ongoing. (2% effort) $45,860.00
5. Principal Investigator; ZA-203 Ext REPROS; A Randomized, Double-Blind, Placebo-Controlled Parallel, Multicenter, Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels. Repros Therapeutics, Inc. 2010-ongoing (2% effort) $51,996.00
6. Principal Investigator; HARMONY 3 GLP112753; A Randomized, Double Blind , Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide. GSK. 2011-ongoing. (2% effort) $118,472.00
7. Sub-Investigator; (P.I.: Brian Miles, M.D.) STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy. Protocol MDV3100-09. MEDIVATION, Inc. 2011-ongoing. (2% effort) $23,396.90
8. Principal Investigator: 178-1008-A Phase 4, double blind, randomized, placebo controlled, multicenter study to evaluate the efficacy, safety and tolerability of mirabegron in men with overactive bladder symptoms while taking tamsulosin for LUTS due to BPH-PLUS- Astellas
9. Principal Investigator; Synergy 178-CL-101: A randomized, Double-Blind, Parallel-Group, Placebo-and Active-Controlled Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder. Protocol #178-CL-101 and 102 v2. Astellas Pharma. 2014-ongoing. (2% effort) $88,675.00

**Pending Protocols:**

1. Principal Investigator; A phase 2 randomized, double-blind, placebo-controlled, study of MR901 in patients with LUTs due to BPH. Mundipharma Research Lts. Cambridge UK, 2015 (Methodist IRB approval pending as of April 15, 2015)

**(All clinical trials listed have been industry-supported.)**

**Non-industry – supported**

Sub Investigator: Miles, B, Mobley, D. Quality of Life and clinical outcomes in men with prostate cancer treated with HIFU

# **K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

Executive Director; The Impotence Foundation Santa Barbara, California 1989-1995

Host/Moderator: Health Talk Houston, Medical Television Show 1989-1992

Executive Director: The Incontinence Foundation. Goleta, California 1989-1992

Regional Medical Director: Impotence Institute of America; Washington D.C. 1992-1996

Host: “Houston Methodist Health Hour” Station AM700 KSEV Radio, Houston 1992-present

Consultant, American Foundation for Urologic Diseas, Baltimore, MD 1993

Board of Trustees, Memorial Foundation, Houston Texas 1994-2001

Board of Advisors- Managed Care in Urology Published by Bard In. 1995

Editorial Board: Journal of Men’s Health 2000-2001

Editorial Board: Medical Aspects of Human Sexuality 1991-1992

Manuscript Reviewer: Journal of Asian Andrology 2014-present

Editorial Board: Asian Journal of Andrology Application in process

**INVITED PRESENTATIONS-SELECTED:**

1. Patch Graft Cystoplasty

South Central Section A.U.A.

San Juan, P.R.

September 27, 1975 (First Place Award)

1. In-Situ Ureteral Graft

South Central Section A.U.A.

September 27, 1975

San Juan Puerto Rico

1. Erythromycin in Treatment of Prostatitis

Kimbrough Annual Seminar

San Antonio TX

October 5-9, 1975

1. Experimental Model for Varicocele

American Urological Association

Las Vegas NV

May 17-20, 1976

1. Replacement of a Large Segment of Ureter with Autologous Ureteral Graft.

American College of Surgeons

Dallas, TX

October 17-21, 1977 (First Place Award)

1. Evaluation of the Impotent Male

AASECT

New Orleans, LA

November 11, 1978

1. Evaluation and Treatment of Impotence: Experience with the Inflatable Penile Prosthesis

Southern Medical Association

Atlanta, GA

November 12, 1978

1. Treatment of Prostatitis

Exhibit

Southern Medical Association

Las Vegas NV

Nov 2-5, 1979

1. Indanyl Carbenicillin in the Treatment of Chronic Bacterial Prostatitis

Delaware Academy of Medicine

Wilmington DE

May 6, 1980

1. Fertility and Vasectomy

Associasion Para Estudio Reproduccion Humana

Monterrey Mexico

August 10-12, 1980

1. Carbenicillin vs. TMP-SMX in the Treatment of Prostatitis

Scientific Exhibit

American Academy of Microbiology

Dallas TX

March 1, 1981

1. Chronic Prostatitis

Pennsylvania State Medical School

Hershey PA

February 15, 1982

1. Surgical Treatment of Male Impotence

Texas Psychological Association Annual Meeting

Houston TX

December 1981

1. Applied Model for Effective Diagnosis and Treatment of Impotence A Team Approach and Algorithm

(Presented with Avi Raphaeli, Ph.D.)

Sixth Annual World Sexology Conference

Washington DC

May 25, 1983

1. Percutaneous Removal of Renal Calculi

Presented to Association of Surgical Technologists, Inc.

Body Human Seminar

Houston TX

September 15, 1984

1. A Sixteen-week, Double-Blind, Placebo Controlled, Dose-Titration Study

Using Doxazosin Tablets For the Treatment of BPH in Normotensive Pts.

Presented to American Urological Association Meeting, in conjunction with

Dr. J. Gillenwater. San Antonio TX. May 1993.

1. Doxazosin: Improved Urodynamics and Symptomatology in Normotensive BPH Patients

Presented with Jay Gillenwater, M.D.

International Prostate Symposium

Paris, France, July 1993

1. Update in the Management of Benign Disease of the Prostate

A national teleconference video

Sponsored by the National Institutes of Health

Bethesda, MD

October 26, 1993

1. The Effect of Zanoterone, a Steroidal Androgen Receptor Agonist in Men with Benign Prostatic Hypertrophy.

Presented to American Urological Association Meeting

San Francisco, CA May 15, 1994

1. Physicians on a Tightrope.

Presented to Annual Meeting Oklahoma Urological Association

Aston, OK, April 16.1994

1. Doxazosin in the Management of Symptomatic BPH. Results with 566 Results with 566 Patients.

Presented to the Annual Meeting American Urological Association

San Francisco, CA May 16, 1994

1. Safety of Doxazosin in the Treatment of BPH

Presented to Annual Meeting, American Urological Association

Las Vegas, NV April 24, 1995

1. Doxazosin in the Management of Benign Prostatic Hyperplasia

Presented to 3rd International Consultation on BPH

Monaco, June 27, 1995

1. BPH, Past, Present and Future:

Presented to South Central Section, American Urological Association

Annual Meeting

Kansas City, MO. September 10, 1995

1. Medical Management of Benign Prostatic Hyperplasia

Moderator of Symposium

Speaker

Presented to primary care symposium/The PROTECT system

Broken Arrow, OK. Sept 21, 1995.

1. Educating the Primary Physician on Evaluation and Treatment of BPH Patients Nuances of Newer Therapies for BPH

Presented to Annual Kibrough Urological Seminar

Washington, DC. November 30, 1995

1. Doxazosin in Patients with BPH: Effects as a Function of Baseline Disease Severity.

Presented to Annual Meeting American Urological Association

Orlando FL. May 7, 1996

1. 26-Week Efficacy and Safety of Doxazosin in the Treatment of Benign Prostatic Hyperplasia

Presented to: European Association of Urology Annual Meeting

Paris, France. Sept 1, 1996

1. Visiting Professorship: Techniques Of Penile Implant Surgery

Hospital Provincial, Oviedo, Spain. September 15, 1997

1. Visiting Professorship: Techniques of Penile Implant Surgery

Lecture in Pre and Post-operative Care

Hospital Carlos Alla Malaga, Spain. September 16, 1997

1. Visiting Professorship/Urology: Techniques of Infrapubic vs.

Penoscrotal Approach in Penile Prosthesis Surgery

Hospital Universario de Granada

Granada, Spain. September 17, 1997

1. Visiting Professorship/Urology: Techniques in Management of

Post Infection Implant Surgery.

Hospital Universario del Rio Herrero Valladolid Spain. September 18, 1997

1. Visiting Professorship; Hospital General De Jerez. Teaching Penile

Prosthesis Surgery and Lecturing on Trouble-Shooting Penile Implant

Surgery. Jerez, Spain. November 3, 1997

1. Visiting Professorship; Hospital General de Albacete; Teaching Penile

Prosthesis Surgery; Lecture: Complications of Implant Surgery.

Albacete, Spain. November 4, 1997

1. Visiting Professorship; Hotel Doce de Octubre.

Teaching Penile Prosthesis Surgery; Lecture: Avoiding and Managing

Penile Prosthesis Problems. Madrid Spain. November 5, 1997

1. Visiting Professorship; Hospital Virgen del Mar. Madrid Spain. Surgical

Management of the Difficult Implant Patient. Treatment of Severe

Fibrosis. Madrid, Spain. November 6, 1997

1. The Importance of Exercise in the Elderly Patient. Presented as Keynote address to Senior Olympics Houston, TX. March 11, 1999
2. Experience with the Harmonic Scalpel In Radical Prostatectomy. Presented to Academia Peruana Conference. Lima, Peru. March 7, 2000
3. Influence Sling Procedure in the Management of Stress Incontinence.

Presented to Academia Peruana Conference. Lima, Peru. March 7, 2000

1. Use of Cox-2 Inhibitors in Urology. Presented to Department of Urology. Louisiana State University Medical School. Shreveport, LA. March 28, 2001
2. The Influence Sling Procedure in the Treatment of Female Stress Incontinence. Continuing Education Course. Hospital Central Militar. Mexico City, Mexico. April 21, 2001
3. Visiting Professorship: Hospital Central Militar, Mexico City. Surgical Demonstration of Female Sling Procedures. Mexico. April 21, 2001
4. The Physiology of Muscarinic Receptors in the Human Bladder. Presented to State-of-the-Art Lecture Series. Atlanta, GA. June 22, 2002
5. Update on BPH/LUTS. Presented at Below the Beltline Conference. Houston TX. Feb 28, 2015
6. Early History of the inflatable penile implant, from someone who was there. Invited faculty. To be presented to 21st Annual Scientific Meeting of Sexual Medicine Society of North America. Las Vegas, NV. November 20, 2015.

**UNITED STATES PATENT:**

Patent number 4043346

August 23, 1977

Urethral Catheter. Developed with Dr. Neil Baum and Baylor College of Medicine.

**L. BIBLIOGRAPHY**

**Peer Reviewed Articles**

1. **Mobley DF**. [Hafnia septicemia.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/5552027) South Med J. 1971 Apr;64(4):505-6. No abstract available. PMID: 5552027
2. **Mobley DF**. [Familial vesicoureteral reflux.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/4767170) Urology. 1973 Nov;2(5):514-8. PMID: 4767170
3. **Mobley DF**. [Erythromycin plus sodium bicarbonate in chronic bacterial prostatitis.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/4591412) Urology. 1974 Jan;3(1):60-2. No abstract available. PMID: 4591412
4. **David F. Mobley**. Chronic Prostatitis. [South Med J.](http://www.ncbi.nlm.nih.gov/pubmed/4590619) 1974 Feb;67(2):219-24.
5. **Mobley DF**. [Left spermatic vein cortisol in subfertile men with varicocele.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/4822695) Urology. 1974 Apr;3(4):461-4. No abstract available. PMID: 4822695
6. **Mobley DF**, Griffith DP. [Acute urinary retention in a child due to procolpos and pyometrium.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/4836345) Urology. 1974 Jun;3(6):784-6. No abstract available. PMID: 4836345
7. [Baum N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Baum%20N%5BAuthor%5D&cauthor=true&cauthor_uid=1090050), [**Mobley DF**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mobley%20DF%5BAuthor%5D&cauthor=true&cauthor_uid=1090050), [Carlton CE Jr](http://www.ncbi.nlm.nih.gov/pubmed/?term=Carlton%20CE%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=1090050). Ureteral replacements. [Urology.](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ureteral+Replacements+mobley) 1975 Feb;5(2):165-71.
8. **Mobley DF**. [Semen cultures in the diagnosis of bacterial prostatitis.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1095783) J Urol. 1975 Jul;114(1):83-5. PMID: 1095783
9. **Mobley DF**. [Metastatic carcinoma of prostate masquerading as abdominal aortic aneurysm.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1136094) Urology. 1975 Jun;5(6):796-8. PMID: 1136094
10. **Mobley DF**, Guthrie TH. [Renal cell carcinoma metastatic to urinary bladder.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/941363) Urology. 1976 Jul;8(1):53-4. PMID: 941363
11. **Mobley DF**. [Phenoxybenzamine in the management of neurogenic vesical dysfunction.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1003641) J Urol. 1976 Dec;116(6):737-8. PMID: 1003641
12. **Mobley DF**. [Studies in ureteral regeneration: replacement of a large segment of ureter with an in situ pedicle graft of proximal ureter.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/836464) Invest Urol. 1977 Jan;14(4):269-73. PMID: 836464
13. Nishimura T, **Mobley DF**, Carlton CE Jr. [Clinical use of immunoelectrophoresis of split ejaculates. I. Variation of patterns due to antisera.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/556657) Urology. 1977 Jan;9(1):39-41. PMID: 556657
14. Nishimura T, **Mobley DF**, Carlton CE Jr. [Immunoglobulin A in split ejaculates of patients with prostatitis.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/841786) Urology. 1977 Feb;9(2):186-7. PMID: 841786
15. **Mobley DF**. [Bacterial prostatitis: treatment with carbenicillin indanyl sodium.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/7019153) Invest Urol. 1981 Jul;19(1):31-3. PMID: 7019153
16. Kostas CI, **Mobley DF**, Rous SN, Schneider RE, Burt RA. [Treatment of urinary tract infection with cephalexin.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/6864165) J Fam Pract. 1983 Jul;17(1):135, 138-40. No abstract available. PMID: 6864165
17. **David F. Mobley**. Choosing a Penile Prosthesis. Medical Aspects of Human Sexuality. 1987;21(5)30-36.
18. **David F. Mobley.** A New Simplified Technique for Implantation of Penile Prosthesis Reservoir. Colleagues in Urology. 1988;2(3):5.
19. **David F. Mobley**. Penile Prosthesis Malfunction. Medical Aspects of Human Sexuality. 1990;24:69-71.
20. **David F. Mobley**. Penile Curvature: Brief Communication. Medical Aspects of Human Sexuality. 1990;24:12-13.
21. **David F. Mobley**, Ken Goldberg, and Steve Wilson. Management of Urinary Incontinence, Part I. Geriatric Medicine. 1991;10(9):19-35.
22. **David F. Mobley**. Kidney Stones. Health and Fitness 1991;7(3):15.
23. **Mobley D,** Raphaeli, A. Postcoital depression. Medical Aspects of Human Sexuality. 1992;26(2):6. (Q & A section)
24. Baum N, Suarez G, **Mobley D**. [Use of infra-pubic incision for insertion of Mentor Mark II inflatable penile prosthesis.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1580033) Urology. 1992 May;39(5):436-8. PMID: 1580033
25. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, **et al.** [The effect of finasteride in men with benign prostatic hyperplasia. \*The Finasteride Study Group.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1383816) N Engl J Med. 1992 Oct 22;327(17):1185-91. PMID: 1383816 (Mobley in study group)
26. Randrup E, Wilson S, **Mobley D**, Suarez G, Mekras G, Baum N. [Clinical experience with Mentor Alpha I inflatable penile prosthesis. Report on 333 cases.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/8379030) Urology. 1993 Sep;42(3):305-8. PMID: 8379030
27. Berger BM, Naadimuthu A, Boddy A, Fisher HA, McConnell JD, Milam D, **Mobley D**, Rajfer J. [The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. \*The Zanoterone Study Group.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/7543598) J Urol. 1995 Sep;154(3):1060-4. PMID: 7543598
28. **Mobley DF**, Baum N. [Interstitial cystitis. When urgency and frequency mean more than routine inflammation.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/8650086) Postgrad Med. 1996 May;99(5):201-4, 207-8, 214. PMID: 8650086
29. Lepor H, Kaplan SA, Klimberg I, **Mobley DF**, Fawzy A, Gaffney M, Ice K, Dias N. [Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/8996348) J Urol. 1997 Feb;157(2):525-30. PMID: 8996348
30. **Mobley DF**, Kaplan S, Ice K, Gaffney M, Dias N. [Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/9489085) Int J Clin Pract. 1997 Jul-Aug;51(5):282-8. PMID: 9489085
31. **Mobley, D**.**F.,** and Baum, N.H. Management of Impotence in the Geriatric Man. Clinical Geriatrics 1998;6(9):58-63.
32. **Mobley DF**, Dias N, Levenstein M. [Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/9522108) Clin Ther. 1998 Jan-Feb;20(1):101-9. PMID: 9522108
33. **Mobley DF**, Baum N. [When patients request the impotence pill.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/9721579) Postgrad Med. 1998 Aug;104(2):55-8, 61-2, 65-6. Review. PMID: 9721579
34. **Mobley, D**.**F.,** Baum, N.H. Sildenafil in elderly men: Advice and caveats. Clinical Geriatrics 1999;7 (12):34-41.
35. Anderson, R., **Mobley, D**.**F.,** et. al. Comparative Efficacy and Safety of a Once-a-Day Controlled Release and an Immediate Release Oxybutyinin Chloride in the Treatment of Patients with Urge Urinary Incontinence. Journal of Urology. 1999;161(6):1809-12.
36. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J. [Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. **PLESS Study Group.**](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10510925) Urology. 1999 Oct;54(4):662-9. PMID: 10510925 (Mobley in study group)
37. Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE.  [Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10210394) **OROS Oxybutynin Study Group.** J Urol. 1999 May;161(5):1551-5. PMID: 10210394 (Mobley in study group)
38. Anderson RU, **Mobley D**, Blank B, Saltzstein D, Susset J, Brown JS. [Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10332441) J Urol. 1999 Jun;161(6):1809-12. PMID: 10332441
39. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J. [Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. **PLESS Study Group**. Proscar Long-term Efficacy and Safety Study.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10510926) Urology. 1999 Oct;54(4):670-8. PMID: 10510926 (Mobley in study group)
40. Versi E, Appell R, **Mobley D**, Patton W, Saltzstein D. [Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10775736) Obstet Gynecol. 2000 May;95(5):718-21. PMID: 10775736
41. Dula E, Keating W, Siami PF, Edmonds A, O'neil J, Buttler S. [Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. **The Apomorphine Study Group.**](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/10869641) Urology. 2000 Jul;56(1):130-5. PMID: 10869641 (Mobley in study group)
42. Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J. [Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. **The Pless Study Group**.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/11018616) Urology. 2000 Oct 1;56(4):610-6. PMID: 11018616 (Mobley in study group) (Mobley in study group)
43. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, **Mobley D**, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group. [Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/11377309) Urology. 2001 Jun;57(6):1073-7. PMID: 11377309
44. Roehrborn CG. [Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/11744466) **ALFUS Study Group.** Urology. 2001 Dec;58(6):953-9. PMID: 11744466 (Mobley in study group)
45. Matsumoto AM, Tenover L, McClung M, **Mobley D**, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J; Pless Study Group. [The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/11956450) J Urol. 2002 May;167(5):2105-8. PMID: 11956450
46. **Mobley, D**., Baum, N. Management of Benign Prostatic Hyperplasia in the elderly patient. Geriatrics and Aging. 2004;7(6):23-28.
47. Girard L, Baum N, **Mobley D.** Urinary Symptoms in patients with low back pain. J Pain Mgmt. 2013;6(2):105-16.
48. **Mobley DF**, Baum N. [Etiology, evaluation, and management of nocturia in elderly men and women.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/24685979) Postgrad Med. 2014 Mar;126(2):147-53. PMID: 24685979
49. Baum N, **Mobley D**, Perito P. Improving operating efficiency with emphasis on prosthetic surgery. Asian J Androl. 2015 March;17:1-3. Epub ahead of print. doi: 10.4103/1008-682X.142146.
50. **Mobley D**. Early history of inflatable penile prosthesis surgery: A view from someone who was there. Asian J Androl. [Asian J Androl.](http://www.ncbi.nlm.nih.gov/pubmed/25432494) 2015 Mar-Apr;17(2):225-9. doi: 10.4103/1008-682X.140962.
51. [**Mobley D**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mobley%20D%5BAuthor%5D&cauthor=true&cauthor_uid=25823641), [Feibus A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Feibus%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25823641), [Baum N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Baum%20N%5BAuthor%5D&cauthor=true&cauthor_uid=25823641). Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment. [Postgrad Med.](http://www.ncbi.nlm.nih.gov/pubmed/?term=Management+of+Benign+Prostatic+Hyperplasia+mobley) 2015 Apr;127(3):301-7. doi: 10.1080/00325481.2015.1018799.
52. Khera M, Baum N, **MOBLEY D.** Current management of erectile dysfunction. Accepted for publication, Post Grad Med 2016.
53. Miller, S, **MOBLEY, D,** Watchful waiting vs. active surveillance: Whch treatment option is right for patients with localized prostate cancer? Urol & Neph. Open Access J. 2018;6(6)173-176.

**Publications In Progress:**

**Mobley DF,** Baum N. Smoking-It's Impact on Urological Conditions; A Review of the Literature. Urology. manuscript number: URL-D-15-00562. In review- Urology March 2015

**MOBLEY D,** Baum N. Obesity and its impact on urological practice. In review for publication: Urology Practice.

**MOBLEY D,** Baum,N. Hypochondria-when imagination becomes disease. Accepted for publication. Oschner Medical Journal 2018

**Books, Book Chapters and Reviews:**

**Book**

1. **David F. Mobley** and Steven K. Wilson: Impotence, It's Reversible. Southwest Impotency Center. VanBuren AK 1990.
2. **Mobley D** and Wilson SK. Reversing Impotence Forever! (The Male Sexual Well-Being Series). Edited by J Pepe and P Billac. Swan Pub Co (September 1995). ISBN-10: 0943629160; ISBN-13: 978-0943629162

**Book Chapter**

1. **Mobley, David** and Baum, N.H. "Office Evaluation of the Impotent Man." *Male Infertility and Sexual Dysfunction*. New York: Springer New York, 1997. 335-339.

**Reviews**

1. **David F. Mobley,** J. Martinez. Two histologically different primary carcinomas of the lung. A review of the literature and presentation of a case. [Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/?term=Two+Histologicaly+Different+Primary+martinez) 1968 Aug;22(2):287-92.
2. **Mobley DF**. [Chronic prostatitis.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/4590619) South Med J. 1974 Feb;67(2):219-24. Review. PMID: 4590619
3. Baum N, **Mobley DF**, Carlton CE Jr. [Ureteral replacements.](http://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/pubmed/1090050) Urology. 1975 Feb;5(2):165-71. Review. PMID: 1090050

**Other Publications**

**Tapes**

1. **Mobley, D**. McMurray, James, Mulcahy, J: Helping Your Impotent Patients Make a Treatment Decision: Produced by American Medical Systems. 1989.
2. **Mobley, D**., Baum, N., Gottesman, J.: Roundtable Forum on Practice Management: Prepared by American Medical Systems, 1993.
* Patient Relations
* Physician and Community Relations
* Managing the Business Side of a Urology Practice
1. **Mobley, D**., Baum, N., Eid, F ; A Primer on Marketing Your Practice Produced by American Medical Systems. April 1997

**BROCHURE:**

**Mobley, D**.F., Feinstein, C., Garber, B.: et. al. Building your Impotence Practice Through Medical Marketing. American Medical Systems 1997

## Abstracts

1. Appell, R, **Mobley, D**.F. et. al.: Comparison of Urge Incontinence Treatments. Submitted for presentation at 1999 American Urological Association annual meeting. May 1-6, 1999. Dallas, TX.
2. Appell, R., **Mobley, D**.F. et. al. Factors influencing patient Response to Controlled-Release Oxybutinin: A Meta-Analysis of Randomized Trials. 1999 American Urological Association annual meeting. May 1-6, Dallas, TX
3. Anderson, R., Gittleman, M. **Mobley, D**.F. et al. The Effect of Age on Efficacy, Safety and Tolerability of Once-Daily Oxybutyin Chloride. 1999 American Urological Association annual meeting. May 1-6, Dallas, TX
4. Brown J, **Mobley D**, et al. Efficacy and tolerability of once-daily oxybutinin chloride versus Ditropan in patients with urge or mixed urinary incontinence. 2015 American Urological Association annual meeting. May 2015. New Orleans, LA.

**Presentations**

1. Carbenicillin in the Treatment of Acute and Chronic Prostatitis

Poster Presentation, Scientific Exhibit

Western Section

American Urological Association

Salt Lake City UT

June 29-July 2, 1981

 (Second Place Award)

Signature:

Date: